American Pharmaceutical Partners(Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for Azithromycin for Injection. The product is the generic equivalent of Pfizer Inc's Zithromax. Azithromycin for Injection is indicated for the treatment of community-acquired pneumonia and pelvic inflammatory disease, when caused by susceptible microorganisms. The product will be available in 500-mg vials. Azithromycin for Injection is preservative-free, and each vial will include a bar code and latex-free vial stopper. For more information, visit www.appdrugs.com.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs